NCT03364985View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

December 3, 2017

Primary Completion Date

May 21, 2019

Study Completion Date

July 30, 2019

Conditions
Healthy
Interventions
DRUG

DWP16001

DWP16001 tablets

DRUG

Placebo

DWP16001 placebo-matching tablets, Active control placebo-matching tablets

DRUG

Dapagliflozin

Forxiga®

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT03364985 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter